Acromegaly is a chronic endocrine disorder characterized by hypersecretion of growth hormone and overproduction of insulin-like growth factor-1. Nearly all cases of acromegaly are caused by an adenoma of the anterior pituitary. A majority of patients are effectively cured by surgical intervention and those who are not receive pharmacological treatment from one of several available drug classes. The bulk of the pipeline of emerging therapies focuses on reformulating existing therapies to improve dosing frequency and route of administration.

Table of contents

  • Acromegaly - Landscape & Forecast - Disease Landscape & Forecast
    • Executive Summary
      • Introduction
        • Key Findings
        • Acromegaly Market Parameters and Forecast
        • Acromegaly SWOT Analysis
    • Commercial Outlook
      • Market Outlook
        • Key Findings
        • Market Overview
        • Acromegaly Market Landscape
      • Drivers and Constraints
        • What Factors Are Driving the Market for Acromegaly?
        • What Factors Are Constraining the Market for Acromegaly?
      • Somatostatin Analogue Specific Trends
        • Somatostatin Analogues
    • Forecast
      • Forecast Sales of Key Therapies in Acromegaly
    • Etiology and Pathophysiology
      • Etiology
        • The Pituitary Gland and Growth Hormone
        • Anterior Pituitary Adenomas
        • Nonpituitary Growth Hormone Excess
        • Genetic Syndromes Associated with Acromegaly
      • Pathophysiology
        • Elevated Growth Hormone and Insulin-Like Growth Factor 1
      • Clinical Presentation
        • Morbidity and Mortality
        • Clinical Presentation of Acromegaly
        • Musculoskeletal Complications
        • Cardiovascular Complications
        • Metabolic Complications
        • Respiratory Complications
        • Neoplastic Complications
      • Key Pathways and Drug Targets
        • Key Pathways and Drug Targets in Acromegaly
        • Key Pathways and Drug Targets in Acromegaly
        • Inhibition of Growth Hormone Secretion
        • Inhibition of Growth Hormone Efficacy
    • Epidemiology Overview
      • Introduction
        • Key Findings
        • Prevalence of Acromegaly per 100,000 Among People of All Ages in 2015 and 2025
        • Relative Sizes of Contributing Factors to Trend in Prevalent Cases of Acromegaly over the Next Ten Years
        • Analysis of Prevalent Cases of Acromegaly in 2015 by Tumor Size
      • Epidemiology Populations
        • Disease Definition
        • Methods
        • Disease Definition
        • Methods
    • Current Treatment Overview
      • Introduction
        • Key Findings
        • Expert Insight
        • Treatment Overview
      • Diagnosis
        • Treatment Providers and Referral Patterns
        • Expert Insight: Diagnosis of Acromegaly
      • Treatment Goals
        • Key End Points Used in Clinical Trials for Acromegaly
        • Key Physician Insights on Clinical End Points
        • Expert Insight: Clinical End Points
      • Key Current Therapies
        • Overview
        • Mechanism of Action of Key Therapies Used for Acromegaly
        • Current Treatments Used for Acromegaly
        • Market Events Impacting the Use of Key Current Therapies in Acromegaly
        • Advantages and Disadvantages of Transsphenoidal Surgery
        • Key Physician Insights on Transsphenoidal Surgery
        • Expert Insight: Transsphenoidal Surgery
        • Clinical Trial Outcomes for Octreotide LAR
        • Advantages and Disadvantages of Octreotide LAR
        • Expert Insight: Octreotide LAR
        • Clinical Trial Outcomes for Lanreotide Depot/Autogel
        • Advantages and Disadvantages of Lanreotide Depot/Autogel
        • Expert Insight: Lanreotide Depot/Autogel
        • Expert Insight: Lanreotide vs. Octreotide
        • Clinical Trial Outcomes for Pasireotide LAR
        • Advantages and Disadvantages of Pasireotide LAR
        • Ongoing Clinical Development
        • Expert Insight: Pasireotide LAR
        • Clinical Trial Outcomes for Dopamine Agonists
        • Advantages and Disadvantages of Dopamine Agonists
        • Expert Insight: Dopamine Agonists
        • Clinical Trial Outcomes for Growth Hormone Receptor Antagonists
        • Advantages and Disadvantages of Growth Hormone Receptor Antagonists
        • Expert Insight: Pegvisomant
        • Advantages and Disadvantages of Radiotherapy
        • Expert Insight: Radiotherapy
      • Medical Practice
        • Overview
        • Acromegaly Treatment Guidelines by Market
        • Factors Influencing Drug Selection in Acromegaly
        • Global Treatment Practices
        • Generalized Treatment Decision Tree for Acromegaly
    • Unmet Need Overview
      • Introduction
        • Key Findings
        • Expert Insight
      • Attainment of Unmet Needs
        • Current Attainment of Unmet Needs in Acromegaly
        • Future Attainment of Unmet Needs in Acromegaly
        • Top Unmet Needs in Acromegaly: Current and Future Attainment
        • Expert Insight: Acromegaly Unmet Needs
    • Emerging Therapies Overview
      • Introduction
        • Key Findings
        • Pipeline Overview
        • Pipeline Trends for Acromegaly
      • Late-Phase Pipeline Analysis
        • Notable Developments in the Late-Phase Pipeline for Acromegaly
        • Therapies in Late-Phase Development for Acromegaly
        • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Acromegaly
      • Orphan Drug Designation
        • Expanded Market Exclusivity
        • Tax Credits
        • Support During the Drug Approval Process
        • Grants
        • Market Exclusivity
        • Fee Reductions
      • Patient Registries
        • Patient Registries for Acromegaly
      • Patient Organizations
        • Prominent Acromegaly Patient Organizations
      • Key Emerging Therapies
        • Mycapssa Profile
        • Mycapssa Clinical Development
        • Key Ongoing Clinical Trials for Mycapssa in the Treatment of Acromegaly
        • Expert Insight
        • Expert Insight: Mycapssa
        • Expectations for Launch and Sales Opportunity of Mycapssa in Acromegaly
        • CAM-2029 Profile
        • Key Ongoing Clinical Trials for CAM-2029 in the Treatment of Acromegaly
        • Expectations for Launch and Sales Opportunity of CAM-2029 in Acromegaly
        • Lanreotide Prolonged Release Formulation Profile
        • Lanreotide Prolonged Release Formulation Clinical Development
        • Key Ongoing Clinical Trials for Lanreotide PRF in the Treatment of Acromegaly
        • Expert Insight
        • Expert Insight on Lanreotide Prolonged Release Formulation
        • Expectations for Launch and Sales Opportunity of Lanreotide PRF in Acromegaly
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Acromegaly
        • Select Early-Phase Compounds in Development for Acromegaly
        • Expert Insight: Select Early-Phase Compounds in Development for Acromegaly
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • Reimbursement Environment for Acromegaly Therapies in the United States
    • Methodology
      • Appendix
        • Key Abbreviations Related to Acromegaly
        • Brands, Marketers, and Generic Availability of Key Therapies for Acromegaly by Market
        • Experts Interviewed
        • Acromegaly Bibliography

    Author(s): Matthew Mackenzie

    Matthew Mackenzie, M.A., is an analyst with the Infectious, Niche, and Rare Diseases Group at Decision Resources Group. Prior to joining Decision Resources Group, Matt  conducted basic science research and led clinical trials in the field of transplant immunology at Beth Israel Deaconess Medical Center/Harvard Medical School, Boston. Matt holds an M.S. in medical sciences from the Boston University School of Medicine and a B.S. in biochemistry and molecular genetics from The University of New Hampshire.